)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Roivant Sciences
Roivant Sciences (ROIV) investor relations material
Roivant Sciences Study result summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Study result summary21 Oct, 2026
Trial design
CLARITY-1 and CLARITY-2 were identical Phase 3 trials enrolling 371 adults with active, non-anterior NIU; participants received brepocitinib 45 mg once daily or placebo for 48 weeks.
The primary endpoint was time to treatment failure from Week 6 to Week 48; oral corticosteroids started at 60 mg, then tapered to zero by Week 8.
Primary efficacy
Both trials met the primary endpoint; median time to treatment failure exceeded 48 weeks with brepocitinib versus 13 weeks in CLARITY-1 and 12 weeks in CLARITY-2 (HR 0.27 and 0.22; p<0.0001 in both).
Pooled Week 48 treatment failure was 33.5% with brepocitinib versus 78.2% with placebo; among prior-TNFi patients, rates were 38.1% versus 77.5%.
Secondary outcomes
Pooled Week 48 steroid-free quiescence was 62% with brepocitinib versus 20% with placebo; results were consistent across subgroups.
Pooled macular edema resolution was 42% with brepocitinib versus 4.8% with placebo; FA response and VFQ-25 response also improved, and all key secondary endpoints were statistically significant in both trials.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Roivant Sciences
- Strong clinical progress and commercial focus drive expansion in autoimmune and orphan indications.ROIV
Bank of America Global Healthcare Conference - FDA approval, best-in-class PH-ILD data, and robust pipeline drive strong outlook.ROIVCitigroup’s Biopharma Back to School Summit 2026
- Mosliciguat's breakthrough data and brepocitinib's promising DM launch drive major pipeline momentum.ROIV12th Annual Cantor Fitzgerald Global Healthcare Conference
- PHocus trial data in PH-ILD and LISRAYA's launch highlight major advances and pipeline momentum.ROIVWells Fargo 21st Annual Healthcare Conference
- Mosliciguat delivered record PVR reduction, functional gains, and strong safety in PH-ILD.ROIVStudy result
- FDA approved LISRAYA as the first targeted oral therapy for dermatomyositis, launching immediately.ROIVFDA announcement
- $950M Moderna payment, $3.9B cash, and key product launch set for September 2026.ROIVQ1 2027
- Proxy covers director elections, auditor ratification, say-on-pay, and highlights governance and ESG.ROIVProxy filing
- Key votes include director elections, auditor ratification, and executive pay approval.ROIVProxy filing
Next Roivant Sciences earnings date
Q2 20279 Nov, 2026
Roivant Sciences
Next Roivant Sciences earnings date
Q2 20279 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Roivant Sciences Ltd. is a commercial-stage biopharmaceutical company established in 2014, dedicated to the development and commercialization of innovative medicines and technologies, particularly in the areas of inflammation and immunology. The company adopts a unique model, creating nimble and focused subsidiaries known as "Vants" for the development and commercialization of its medicines and technologies. This model has enabled Roivant to bring to market treatments like VTAMA® (tapinarof cream, 1%) for plaque psoriasis in adults, and to advance a diverse pipeline of investigational drugs across its family of companies, including fully human monoclonal antibodies and treatments for autoimmune diseases. Roivant Sciences is headquartered in London, United Kingdom, and its shares are listed on the NASDAQ.